There is an urgent need to improve lung cancer risk assessment because current screening criteria miss a large proportion of cases.
T he National Lung Screening Trial (NLST) findings suggested that screening with low-dose computed tomography (LDCT) can reduce lung cancer mortality. 1 As a result, the US Preventive Services Task Force (USPSTF) recommends LDCT screening for lung cancer among individuals aged 55 to 80 years who have smoked 30 pack-years with up to 15 years since quitting smoking. 1, 2 However, LDCT screening results in a large number of indeterminate nodules, 1 and less than 50% of incident lung cancer cases are among individuals who are eligible for screening. 3 Biomarkers may improve lung cancer risk assessment over and beyond traditional smoking-based risk models and improve current screening eligibility criteria. 4, 5 Previous studies have shown that the precursor form of surfactant protein B (Pro-SFTPB) is predictive of lung cancer risk. 5, 6 Other markers that have been shown to be useful for the workup and diagnosis of lung cancer include cancer antigen 125 (CA125), cytokeratin-19 fragment (CYFRA 21-1), carcinoembryonic antigen (CEA), and human epididymis protein 4 (HE4). [7] [8] [9] [10] [11] [12] However, there are limited data regarding the performance of these markers in discriminating between future lung cancer cases and controls. This study aimed to assess the potential of these 5 protein biomarkers to inform about lung cancer risk when tested blindly using prediagnostic samples.
Methods
A full account of the methods is provided in the eMethods in the Supplement. In brief, samples obtained from eversmoking patients with lung cancer (cases) diagnosed within 1 year after blood collection (n = 108) and smoking-matched controls (n = 216) from the US Carotene and Retinol Efficacy Trial (CARET) cohort were used to develop a biomarker score based on circulating measures of Pro-SFTPB, CA125, CEA, HE4, and CYFRA 21-1 using logistic regression. All study participants gave written informed consent to participate in the study, and the research was approved by the institutional review boards of all of the participating institutions.
The extent to which the biomarker score improved discrimination of incident lung cancer cases and controls was validated externally using ever-smoking patients with lung cancer (cases) diagnosed within 1 year after blood collection (n = 63) and matched controls (n = 90) from the European Prospective Investigation into Cancer and Nutrition (EPIC) study and the Northern Sweden Health and Disease Study (NSHDS) (eFigure 1 in the Supplement). Absolute 1-year risks of lung cancer were estimated for each study participant in the validation study by modeling the cumulative hazards of lung cancer using flexible parametric survival models.
13 Two models were evaluated: a traditional smoking history-based risk model and an integrated risk prediction model that combined the smoking model and the biomarker score. Model discrimination was assessed by receiver operating characteristic (ROC) analysis using the predicted 1-year lung cancer risks as scoring rule. Discrimination estimates included area under the ROC curve (AUC), sensitivity, and specificity, which were weighted to reflect the background populations.
In the context of using the 1-year absolute risk of lung cancer to define screening eligibility, the sensitivity provides an estimate of the fraction of future lung cancer cases that would be eligible for screening at a certain absolute risk threshold. Conversely, the specificity provides an estimate of the fraction of individuals from the background population who remain healthy and would not be eligible for screening. A sensitivity of 1.00 (or 100%) would indicate that all lung cancer cases are eligible for screening and a specificity of 1.00 (100%) would indicate that all individuals who remain healthy are not eligible for screening (ie, that there are no false-positive controls). Statistical significance was assumed at a 2-sided P < .05.
Results
Details of the biomarker score and discrimination estimates in the CARET training study are available in eTables 1 and 2 and eFigures 2 and 3 in the Supplement. In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (mean [SD] age, 57.7 [8.7] years; 68.6% men) from EPIC and NSHDS, the predicted risk of receiving a diagnosis of lung cancer within 1 year for a 60-year-old man with 30 pack-years of smoking history was estimated at 0.37% using the smoking model ( Figure 1) . In comparison, using the integrated risk prediction model, we estimated 1-year risks at 0.07% and 1.56% for the same man assuming a biomarker score equal to the average of the first and fourth quartile, respectively. The 1-year lung cancer risk estimates for each study participant in the validation study according to the smoking and integrated risk prediction models are shown in Figure 2 . In comparison with the smoking model, the median 1-year risk estimates from the integrated risk prediction model increased for cases from 0.27% (interquartile range [IQR], 0.14%-0.50%) to 0.45% (IQR, 0.18%-1.5%) and decreased for controls from 0.12% (IQR, 0.05%-0.21%) to 0.04% (IQR, 0.015%-0.17%).
In the validation study, the population-weighted AUC was 0.73 (95% CI, 0.64-0.82) for the smoking model and 0.83 (95% CI, 0.76-0.90) for the integrated risk prediction
Key Points
Question Can a risk prediction model based on circulating protein biomarkers improve on a traditional risk prediction model for lung cancer and the current US screening criteria?
Findings In a validation study of 63 ever-smoking patients with lung cancer and 90 matched controls, a biomarker-based risk prediction model consisting of 4 protein markers that was developed in a cohort of US individuals at high risk of lung cancer outperformed a model based on smoking history alone when blindly validated using prediagnostic samples from 2 European cohorts.
Meaning Biomarker-based risk profiling has the potential to improve eligibility criteria for lung cancer screening.
model (P = .003 for difference in AUC) ( Figure 3A) . The AUCs were consistently higher for the integrated model than for the smoking model across relevant strata (eTable 3 in the Supplement). At an overall specificity of 0.83 based on the USPSTF screening criteria, the integrated risk prediction model yielded a sensitivity of 0.63 (95% CI, 0.49-0.76) compared with 0.43 (95% CI, 0.23-0.65) for the smoking model. Similarly, at an overall sensitivity of 0.42 (USPSTF), the integrated risk prediction model yielded a specificity of 0.95 (95% CI, 0.85-0.99) compared with 0.86 (95% CI, 0.72-0.94) for the smoking model. The improvement in AUC for the integrated risk prediction model (AUC, 0.80; 95% CI, 0.75-0.85) over the smoking model (AUC, 0.73; 95% CI, 0.68-0.79) was more modest when cases diagnosed up to 2 years after blood draw were considered (eFigure 4 in the Supplement). A full account of all conducted analyses is provided in the eResults; eTables 1, 2, and 4 to 10; and eFigures 6 to 10 of the Supplement. The validation samples consist of EPIC and NSHDS ever-smoking participants who received a diagnosis of lung cancer within 1 year after blood collection. For the controls, the size of the points is proportional to the number of eligible participants represented (corresponding to the inverse of the sampling probability). The right panel represents a magnified excerpt of the full figure. A, Predicted probability of lung cancer according to the smoking risk prediction model based on age in years and smoking history. The rug plot shows the observed distribution of age in the validation study (European Prospective Investigation into Cancer and Nutrition [EPIC] and NSHDS, ever smokers). B, Predicted probability of lung cancer according to the integrated risk prediction model based on the biomarker score and the smoking history. The rug plot shows the observed distribution of the biomarker score in the validation study (EPIC and NSHDS, ever smokers). The vertical lines correspond to the quartiles threshold for biomarker score among controls (Q1, Q2, Q3, and Q4). 
Discussion
This is, to our knowledge, the first study in which a bloodbased biomarker score was developed using one cohort and externally validated using prediagnostic samples from other independent cohorts. We observed a notable improvement in discrimination between future lung cancer cases and controls over a traditional smoking-based risk prediction model by incorporating information from a biomarker score consisting of 4 circulating proteins. In our validation study, 26 of the 62 incident lung cancer cases (42%, corresponding to a sensitivity of 0.42) would have qualified for LDCT screening according to USPSTF criteria (USPSTF eligibility criteria could not be assessed for 1 case). Using the biomarker score together with smoking information, we estimated that 40 of 63 cases (63%, corresponding to a sensitivity of 0.63) could be identified without increasing the number of eligible controls (ie, without decreasing the specificity). The data further suggested that the biomarker score could alternatively be used to reduce screening of individuals not destined to develop lung cancer (false positives) from 15 of 90 controls (17%) to 4 of 90 controls (5%) without affecting the uptake of future lung cancer cases (sensitivity). These improvements in sensitivity and specificity were consistently observed across each evaluated stratum. Our findings also indicated that the improvement in discrimination afforded by the biomarker score is more modest beyond the initial year after blood draw, which suggests that an annual biomarker test may be necessary in a screening program.
Strengths and Limitations
Naive discrimination estimates, as typically provided in a matched, nested, case-control setting, are inherently biased. An important strength of our study was the use of absolute risks and population-based discrimination estimates, which were necessary to estimate the number of individuals who would be selected for screening using the biomarker-based eligibility criterion in the overall background cohorts, beyond our specific case-control study.
A limitation of our study was that 3 variables that were originally included in a validated risk prediction model (the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial model from 2012 [PLCO M2012 ]) were not available in our validation studies.
14 However, with use of the original PLCO data, the exclusion of these variables from the PLCO M2012 model only nominally decreased the model's performance, which suggests that our risk prediction model represented a valid comparison for the biomarkers score (eMethods and eFigure 5 in the Supplement).
14 Although this study provided a proof of principle of the potential of using biomarkers in lung cancer risk assessment to define screening eligibility, validating and calibrating the integrated risk prediction model using larger sample size with prediagnostic samples is clearly needed before such a risk prediction tool can be used in practice. A larger sample size will also allow stratified analysis to evaluate the performance of the biomarker panel in predicting lung cancer cases associated with different characteristics, such as stage at diagnosis and histologic subtype. Furthermore, our study was limited to a select panel of circulating proteins, and we note that other types of biomarkers may also be informative. 4, 5 We also note that the population that would most benefit from a biomarker test before undergoing LDCT screening remains to be defined. A thorough costeffectiveness assessment based on a large study sample is warranted to determine the threshold in absolute risk of developing lung cancer during a specific period, above which the benefits of screening outweigh the harms.
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Conclusions
This study provides a proof of principle in demonstrating that circulating biomarkers have the potential to inform lung cancer risk assessment and substantially improve on current criteria for LDCT screening. Role of the Funder/Sponsor: The funding organizations had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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eMethods. Supplementary Methods
Development of a biomarker score in the CARET training study CARET was a randomized, double-blind, placebo-controlled trial evaluating the cancer prevention efficacy and the safety of daily supplementation with beta-carotene and retinol palmitate in 18,314 persons at high risk for lung cancer. 1, 2 Participants were enrolled at 6 US centers from 1985 to 1994 and were followed for cancer and mortality outcomes until 2005. Aliquots of pre-diagnostic serum samples from CARET participants previously utilized in a blinded validation study of Pro-SFTPB 23 were used to test the individual performance of CA125, CEA, HE4 and CYFRA 21-1 and develop a risk prediction biomarker score. In total, samples were assayed from 108 subjects who subsequently developed non-small-cell lung cancer (NSCLC) within 12 months after providing a blood sample, and 216 controls comprising two controls matched to each case based on age at baseline (5-yr groups), sex, baseline smoking status (current vs former), and study enrollment period.
Performance of the biomarker score in the EPIC and NSHDS validation study
The EPIC study is an ongoing multi-center prospective cohort that recruited participants between 1992 and 1998. The current study was defined amongst 267,377 participants from Greece, Netherlands, UK, France, Germany, Spain, and Italy who donated a blood sample at study recruitment. NSHDS is an ongoing prospective cohort of the general population of the Västerbotten County in Sweden. As of 2014, the cohort had recruited 99,404 study participants who donated a blood sample at recruitment. 3, 4 Incident cancer cases within the studies were identified using combination of passive and active follow-up. 3, 4 Lung cancer was defined based on the International Classification of Diseases for Oncology (ICD-O-2), and included all invasive cancers that were coded as C34. The validation study included incident cases diagnosed within 1 year of blood draw, (N=67) and cases diagnosed within 2 years of blood draw (N=85) (eFigure 1). For each index case, two controls were chosen from risk sets consisting of all cohort members alive and free of cancer (except nonmelanoma skin cancer) at the time of diagnosis of the index case. Matching criteria were study center, sex, date of blood collection (±12 months), and age at blood collection (± 3 months, relaxed up to ± 5 years). In order to improve the statistical power in smoking stratified analyses, one of the controls was additionally matched based on smoking status of the index case from 5 categories; never smokers, short and long term quitters among former smokers (<10 years and 10 years since quitting, respectively), and light and heavy smokers among current smokers (<15 cigarettes and 15 cigarettes per day, respectively). All study participants gave written informed consent to participate in the study and the research was approved by the local ethics committees in the participating countries, as well as the IARC and MD Anderson Ethical Review Committees.
Laboratory methods
Samples from all study participants for both training and testing, were sent on dry ice blinded to case-control status to the laboratory at MD Anderson Cancer Center, where they were kept below −80°C until analysis. Concentrations for Pro-SFTPB, CA125, CEA, CYFRA 21-1 and HE4 were determined using bead-based immunoassays on the MAGPIX® instrument (Luminex Corporation, Austin TX). Samples were analyzed in batches of 36 samples in duplicates with matched cases and controls in the same batch in random order. Quality control procedures included 7 calibration standards, 2 Quality Control samples, and 1 blank sample run in duplicate in each batch. The coefficients of variation (CVs) within and between batches were, 6.86% and 15.54% for CA125, 1.45% and 9.32% for CEA, 6.55% and 17.26% for Pro-SFTPB, 5.56% and 28.71% for CYFRA 21-1, and 10.334 % and 12.997% for HE4, respectively.
Statistical methods
Data for each evaluated biomarker was initially log-transformed. Data from the CARET training study was used to develop a biomarker score. Because data for CYFRA 21-1 was missing from some CARET samples due to prior sample depletion, model building employed a two-stage approach wherein the first stage involved selecting a biomarker panel using data for CA125, CEA, HE4, and Pro-SFTPB by logistic regression based on Akaike Information Criterion (AIC). The second stage involved combining the risk model attained from the first stage with data on CYFRA 21-1 using logistic regression. Using Receiver Operating Curve (ROC) analyses, we evaluated the AUC for a biomarker score with and without CYFRA 21-1 in order to establish a final biomarker score. Because of lack of additive performance, HE4 was dropped out from the biomarker panel. The biomarker score was subsequently validated in ever smokers from EPIC and NSHDS (63 cases and 90 matched controls). To determine the extent to which the biomarker score could improve on a risk prediction model based on smoking exposure history, we fitted a smoking-model using data from EPIC and NSHDS that were not used in the validation study, defined by cases diagnosed 2 to 10 years after study recruitment with controls individually matched with the same matching criteria as in the validation study (886 ever-smoking cases and 1,349 ever-smoking controls). With use of conditional logistic regression, parameters for the smoking-model were fitted for smoking status (former vs. never, current vs. never), number of cigarettes per day for current smokers (continuous [not available in former smokers]), smoking duration (continuous in former and current smokers), and time since quitting for former smokers (continuous). The extent to which the biomarker score and smoking-based score could discriminate between incident lung cancer cases and controls was subsequently evaluated externally and non-parametrically by assigning the respective risk scores to each participant in the validation study (cases diagnosed 0 to 1 year after blood draw, and subsequently expanded to 0 to 2 years after blood draw). In addition, in order to evaluate the potential of combining the two risk scores, an integrated risk prediction model was developed by fitting a conditional logistic regression model using the smoking-based score and biomarker score as two separate covariates in the validation study. In order to provide absolute risk and discrimination estimates reflecting the background population of the validation studies, we used the pseudo-likelihood approach of Samuelsen et al. 5 . We subsequently modelled the cumulative hazards of lung cancer using flexible parametric survival models 6 for the smoking and integrated risk prediction models to estimate the baseline hazards and the absolute risks of lung cancer over 1 and 2 years. The apparent discriminatory accuracy of the smoking-based score, the biomarker score, and the integrated risk prediction model, were evaluated using ROC analyses in the validation study. The 95% confidence intervals were estimated using 2,000 stratified bootstrap replicates, and differences in AUC estimates were determined using nonparametric methods. 7 To determine the fraction of future lung cancer cases that would have been identified using the different models, we estimated the sensitivity of each model at the specificity level obtained by applying the USPSTF screening eligibility criteria to each subject in the validation study. However, because the controls were individually matched to the cases in the validation study, the apparent specificity estimates will be biased. The final ROC analysis was thus conducted using predicted 1-year and 2-year lung cancer risks as scoring rule, with population-based sensitivity and specificity estimates weighted according to their sampling probability. Statistical significance was assumed at a two-sided P-value below 0.05. All statistical analyses were conducted using R 3.3.0 (R Core Team (2016)) and STATA v.14.2 (StataCorp LP, College Station, TX).
Comparison between the smoking-based risk prediction model used in the current paper and a validated lung cancer risk prediction model.
We compared the discriminative performance of our smoking-based risk prediction model with a model based on the validated PLCO M2012 lung cancer risk prediction model developed in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial 8 . The PLCO M2012 model includes 11 variables and a constant, and was developed for ever smoking subjects only. In the validation study, we did not have access to data on history of chronic obstructive pulmonary disease (COPD), family history of lung cancer, nor intensity of smoking among former smokers and could therefore not include these variables in the comparison model. Since all of our subjects are of white ethnicity, and were selected based on no previous history of cancer, these coefficients were not included in the comparison model. The coefficients we used to build the risk score based on the PLCO M2012 model are shown in eTable 4. First, We compared the discriminative performance of the reduced PLCO model (excluding history of COPD and family history of lung cancer and intensity among former smokers) to the original PLCO M2012 model using the data where the PLCO M2012 model was validated in (80,375 persons in the PLCO control and intervention groups who had ever smoked). The AUC were very similar: 0.80 and 0.78 for the original and modified PLCO models respectively (eFigure 5). The comparison between our smoking-based risk prediction model and the reduced PLCO M2012 model was performed among ever smokers in EPIC and NSHDS who were diagnosed with lung cancer within 1 year of blood collection. Due to some missing values on education, body-mass index, and intensity of smoking, we performed these analyses on 136 subjects (57 cases and 79 controls). We used the PLCO risk score as a covariate in our weighted flexible parametric survival models as described in the methods section of the manuscript for the smoking-based score. An integrated risk prediction model was also built by fitting a model using the PLCO risk score and the biomarker risk score as separate covariates. The discriminatory accuracy of our smoking-based risk prediction model, the PLCO-based risk prediction model, and the two integrated risk prediction models, were evaluated using ROC analyses.
eResults. Supplementary Results
The baseline characteristics of subjects in the training and validation studies are presented in eTable 5.
Training of the smoking risk prediction model
The characteristics of the EPIC and NSHDS sample set used to train the smoking model are presented in eTables 6 and 7. The 1-year probability of lung cancer predicted from the smoking model was similar in the validation study and in the full EPIC cohort (1,161 cases and 114,204 controls; eFigure 6).
Development of a biomarker score based on the CARET training study
The discrimination performances of each candidate biomarker in the CARET training study are presented in eTable 1 and eTable 2. Their AUC estimates ranged from 0.60 (95% CI: 0.53-0.67, CA125) to 0.70 (95% CI: 0.64-0.77, ProSFTPB) at P-value < 0.05. Based on AIC, HE4 was excluded from the model, and the final biomarker score based on four markers (CA125, CEA, CYFRA 21-1 and Pro-SFTPB) yielded an AUC of 0.80 (95% CI 0.72-0.87) in the CARET training study.
Performance of the risk prediction models in discriminating between future lung cancer cases and controls in the validation study All the weighted (according to the sampling probability) models were well calibrated (eFigure 7). Integrating never smokers in the ROC analyses yielded comparable findings to the overall analysis with a 10% increase in AUC when biomarkers were combined to smoking variables (eTable 8, eFigure 8). Among ever smokers, the integrated risk prediction model discriminated similarly for early and late lung cancer stages and the two most prevalent histologic types, with a consistently higher AUC than the smoking-based risk prediction model (eTable 9). Apparent (unweighted) discrimination estimates among subjects diagnosed within 1 year of blood collection are provided in eFigure 9 and eTable 10. This analysis showed a 13% improvement in AUC from the smoking model (AUC=0.77 (95% CI: 0.70-0.85)) to the integrated model (AUC=0.90 (95% CI: 0.86-0.95)).
Comparison between the smoking-based risk prediction model used in the current paper and a validated lung cancer risk prediction model. In the validation study, the reduced PLCO model yielded similar AUC estimates to our smoking-based risk prediction model (P for difference in AUC > 0.5, eFigure 10). Light smokers: current smokers that smoke < 30 pack-years; c Smoking model: logistic model including smoking status, smoking duration, mean quantity of cigarettes smoked/day (for current smokers), time since quitting smoking (for former smokers) fitted in EPIC and NSHDS samples including cases diagnosed between 2 to 10 years from blood draw. 
